PRECLINICAL PROMISE OF BECAPLERMIN (RHPDGF-BB) IN WOUND-HEALING

Advances in molecular biology have made possible the production of hig hly purified recombinant human proteins, and recombinant human growth factors have emerged as potential therapeutic wound healing agents. Be caplermin (recombinant human platelet-derived growth factor-BE [rhPDGF -BB]) quickly emerged as one of the leading candidates for clinical tr ials. Before the expected therapeutic potential of rhPDGF-BB and other growth factors could be realized, a number of concerns had to be addr essed (eg, would growth factors show effects in normal animals, what p arameters of wound healing would be affected, and would quality of hea led wounds be normal?). In animal models, rhPDGF-BB demonstrated wound healing activity, predominantly by enhancing the formation of granula tion tissue, but it was not known whether this effect on granulation t issue would translate into enhanced healing of chronic skin ulcers in humans. The objective of this article is to review how the study of rh PDGF-BB in animal wound healing models has assisted in addressing the potential clinical utility of rhPDGF-BB. Results of animal studies are summarized, and the advantages and limitations of the animal models a re discussed. Am J Surg. 1998;176(Suppl 2A):48S-54S. (C) 1998 by Excer pta Medica, Inc.